Toggle light / dark theme

Unique communication strategy discovered in stem cell pathway controlling plant growth

A team of plant geneticists at Cold Spring Harbor Laboratory (CSHL) has identified a protein receptor on stem cells involved in plant development that can issue different instructions about how to grow depending on what peptide (protein fragment) activates it.

This is the first such multi-functional receptor found to work in this way to control . The new findings obtained by CSHL Professor David Jackson and colleagues may have important implications for efforts to boost yields of essential food crops such as corn and rice.

Plant growth and development depend on structures called meristems — reservoirs in plants that contain . When prompted by peptide signals, stem in the meristem develop into any of the plant’s organs — roots, leaves, or flowers, for example. These signals generally work like a key (the peptide) fitting into a lock on the surface of a cell (the ). The lock opens momentarily, triggering the release of a inside the cell. The messenger carries instructions for the cell to do something, such as grow into a root or flower cell or even stop growing altogether. Conventionally, one or more peptides fit into a receptor to release a single type of chemical messenger.

Treating Heart Failure

Researchers at the University of Alabama at Birmingham have discovered a potential target for therapies that may prevent or delay heart failure from pressure overload of the heart. It could also be a biomarker to warn physicians that a patient is at risk of this happening.

Early macrophage infiltration is a step in heart failure

In a new study, Dr. Sumanth Prabhu and his team showed that preventing the early infiltration of CCR2+ macrophages into the heart, in a mouse model of heart failure, significantly reduced enlargement of the heart and the decline of the pumping ability that leads to heart failure [1]. This means that the infiltration of macrophages is a critical step in heart failure.

13-Year-Old Boy Is First Person in US to Receive Newly Approved Gene Therapy for Blindness

On Tuesday, a 13-year-old boy from New Jersey was at the center of medical history as he became the first person in the US to receive an FDA-approved gene therapy for an inherited disease. The event marks the beginning of a new era of medicine, one in which devastating genetic conditions that we are born with can be simply edited out of our DNA with the help of modern biomedical technologies.

The therapy, Luxturna, from Spark Therepeutics, was approved by the FDA in December to treat a rare, inherited form of blindness. Its price tag, set at $850,000—or $425,000 per eye—made it the most expensive drug in the US and sparked mass sticker-shock. But the therapy, which in high-profile clinical trials has allowed patients to see the stars for the first times, also offered the almost miraculous possibility of giving sight to the blind.

The therapy is intended to treat retinal diseases, including leber congenital amaurosis or retinitis pigmentosa, caused by mutations in the RPE65 gene. The RPE65 gene produces an enzyme that helps the eye process light. In these disorders, severe visual impairment begins often in infancy, and sometimes degrades over time. Some people with a mutated copy of the gene can see during the day; others are legally blind. The drug works by delivering a correct copy of the RP65 gene to retinal cells, allowing the patient to produce the deficient enzyme—and, hopefully, restoring their vision. (Luxturna is considered by some to be the first “true gene therapy” approved by the FDA, since other approved therapies, like those for blood cancers, involve removing a patient’s cells from their body, modifying them externally, and then infusing them back into the body.)

Anyone Can Now Take This Breast Cancer Gene Test, But It Probably Won’t Tell You Much

Breast and ovarian cancers are scary, anxiety-provoking diseases, and with good reason. Although breast cancer isn’t the cancer that kills the most women (lung cancer holds that distinction), it is the most commonly diagnosed cancer in women. And ovarian cancer is difficult to find in its early stages. But anyone willing to spit in a tube and pay $199 will soon be able to find out if they have a particular genetic predisposition to either of these cancers.

This month, the FDA granted the genetics company 23andMe permission to offer direct-to-consumer testing for three of the more than 1,000 known variants of the genes BRCA1 and BRCA2The variants may also boost the risk of prostate cancer and melanoma.

UK Doctors Used Stem Cells to Restore Eyesight in Two People

British doctors have taken a huge step towards curing a common form of age-related chronic eye condition.

Two elderly patients with macular degeneration at Moorfields Eye Hospital in London were given a cutting-edge stem cell therapy as part of a small trial to improve vision for people with sudden and severe loss of vision caused by what’s known as “wet” macular degeneration, in which abnormal blood vessels grow under the retina and macula in the eye. “Wet” macular degeneration is less common than “dry” macular degeneration, but it is a more severe form of the disease that occurs as “dry” macular degeneration progresses. It rarely causes total blindness, but it can cause blurriness and blind spots that make it hard to see clearly. The idea was to replace those diseased eye cells using stem cells that were derived from a human embryo and then inserted into the back of the eye.

Embryonic stem cells are special because they have the ability to become any other cell type in the human body. In this case, they were coaxed into becoming the kind of cell that makes up the retinal pigment epithelium. They were embedded into a scaffold to hold them in place, a living patch of cells only one layer thick. That patch was then surgically inserted under the rods and cones in the back of the eye.

A drug to slow spread of dementia could be available in three years

A drug to slow the spread of dementia could be available in three years and a ‘vaccine’ that prevents the disease within a decade, experts say.

  • It is now a matter of ‘when not if’ a cure will be found for Alzheimer’s
  • Last year dementia became Great Britain’s number one cause of death
  • Existing drugs for Alzheimer’s only treat the symptoms, not causes

By Colin Fernandez for the Daily Mail